Marcus Pilgerstorfer QC (11KBW) writes for InDret with Jean-Sébastien Borghetti (Université Panthéon-Assas), Duncan Fairgrieve (British Institute of International and Comparative Law), Richard Goldberg (Durham Law School), Geraint Howells (NUI Galway), Piotr Machnikowski (University of Wrocław), Eleonora Rajneri (University of Piemonte Orientale), Peter Rott (University of Oldenburg), Marta Santos Silva (Maastricht University), Vibe Ulfbeck (University of Copenhagen).
The recent release of the Covid-19 vaccine supply contract between the European Commission and Astra Zeneca has caused a political and media storm about vaccine production logistics and supply issues. A lesser noticed but controversial issue revealed by the contract is that of where ultimate liabilities should lie, which has potentially far-reaching consequences for the public purse. Many commercial contracts include so-called indemnity clauses hereby one party contractually agrees to cover liabilities incurred by the other. The European Commission accepted in Article 14 of the agreement an extremely broad indemnity of the manufacturer covering almost any and every defect imaginable whether that be the vaccine’s inherent characteristics, manufacturing / distribution, and storage issues, labelling errors or even problems due to administration of the vaccine. This is a potentially significant burden to place on the state, and ultimately taxpayers.
For further information, please read the full paper here.